Czech/SlovakiaCzech RepublicSlovakia

Oligo enters clinical trials

11.07.2007

Prague/Foster City – An oligonucleotide analogon, originally developed at the Institute of Organic Chemistry and Biochemistry (IOCB) at the Czech Academy of Sciences in Prague, has entered clinical testing as treatment for non-Hodgkin lymphoma and chronic lymphocytic leukaemia. In mid-June the US biopharmaceutical company Gilead Sciences kicked off a Phase I study with GS9219, a non-toxic 9-(2-phosphoryl-methoxyethyl)-guanine prodrug that accumulates in lymphatic cells and which Gilead licensed in 1991 from the IOCB. In the last year, Gilead has established a research site in the institute with annual funding of a800,000 million over five years.

Czech/SlovakiaCzech RepublicSlovakia

01.02.2010

Prague – After increasing its investment in mid-January, full-service provider CRO FGK Clinical Research GmbH has become a major shareholder in the Czech contract research organization Avemedica s.r.o. Financial details were not...

Czech/SlovakiaCzech RepublicSlovakia

01.02.2010

Pilzen – German antibody drug development and discovery firm Affimed Therapeutics AG (Heidelberg) has spun-out all of its antibody discovery activities into a new Czech subsidiary – AbCheck s.r.o., which is located in Pilzen....

Czech/SlovakiaCzech RepublicSlovakia

18.09.2009

Prague/Jena – German and Czech researchers under Ales Svatos have opened the door to major improvements in the application of high-throughput metabolomics and systematic analyses of small molecules via MALDI-mass spectrometry...

Czech/SlovakiaCzech RepublicSlovakia

19.07.2009

Ceské Budejovice - The scientists from the Biology Centre of the Czech Academy of Science who coordinated the EU project MOBITAG have tabled a report on their attitudes towards political interference in the EU’s GMO authorisation...

Czech/SlovakiaCzech RepublicSlovakia

14.07.2009

Bratislava – According to a new study released by PG Economics, Slovak farmers would benefit more than counterparts in other EU countries from planting genetically-engineered Bt maize. Regional factors, as well as reducing an...

Czech/SlovakiaCzech RepublicSlovakia

14.07.2009

Vestec – The Czech Academy of Sciences and Charles University plan to build a modern biotechnology and biomedicine center, according to reports issued by the Czech Information Agency. With about 40,000 square meters of floor...

Czech/SlovakiaCzech RepublicSlovakia

13.07.2009

Olomouc – A new cluster with a focus on drug development and diagnostics has been established near Palacky University in Olmouc. Called MedChemBio, the centre seeks to attract companies with an interest in medicinal and...

Czech/SlovakiaCzech RepublicSlovakia

12.07.2009

Prague – A biotech company and a pharmaceutical enterprise are the winners of this year’s “Investor of the Year” competition, which is organised by CzechInvest and the country’s Association for Foreign Investment. At the end of...

Czech/SlovakiaCzech RepublicSlovakia

29.04.2009

Prague – A2Z Bio, the Czech subsidiary of UK-based Yorkshire Bioscience, is investing EUR100,000 at the CKD Prague Technological Innovation Centre to launch production of research reagents and services for the biotech R&D market....

Displaying results 11 to 20 out of 70

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-czech-slovakia/browse/1/article/oligo-enters-clinical-trials.html

Events

All Events

Stock list

All quotes

TOP

  • PHARMING (NL)0.48 EUR11.63%
  • MDX HEALTH (B)3.80 EUR10.79%
  • NEUROVIVE PHARMACEUTICAL AB (S)70.00 SEK8.53%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • NOVACYT (F)4.46 EUR-10.26%

TOP

  • WILEX (D)2.82 EUR231.8%
  • ADDEX (CH)3.80 CHF58.3%
  • NEUROVIVE PHARMACEUTICAL AB (S)70.00 SEK44.9%

FLOP

  • HYBRIGENICS (F)1.72 EUR-29.5%
  • PROSENSA (NL)9.67 USD-23.8%
  • VITA 34 (D)4.18 EUR-20.4%

TOP

  • SANTHERA (CH)59.90 CHF2836.3%
  • GW PHARMACEUTICALS (UK)431.00 GBP676.6%
  • PAION (D)2.42 EUR255.9%

FLOP

  • EVOCUTIS (UK)0.21 GBP-92.6%
  • CYTOS (CH)0.27 CHF-92.0%
  • THROMBOGENICS (B)9.16 EUR-70.4%

No liability assumed, Date: 30.07.2014


Current issue

All issues

Product of the week

Products